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CLINICAL RESEARCH ARTICLE
Inhaled nitric oxide as an adjunct to neonatal resuscitation in
premature infants: a pilot, double blind, randomized controlled
trial
Krishnamurthy Sekar1, Edgardo Szyld1, Michael McCoy1, Anne Wlodaver1, Douglas Dannaway1, Ashley Helmbrecht1, Julee Riley1,
Amy Manfredo1, Michael Anderson1, Satyan Lakshminrusimha2 and Shahab Noori3
BACKGROUND: Nitric oxide (NO) plays an important role in normal postnatal transition. Our aims were to determine whether
adding inhaled NO (iNO) decreases supplemental oxygen exposure in preterm infants requiring positive pressure ventilation (PPV)
during resuscitation and to study iNO effects on heart rate (HR), oxygen saturation (SpO2), and need for intubation during the first
20min of life.
METHODS: This was a pilot, double-blind, randomized, placebo-controlled trial. Infants 25 0/7–31 6/7 weeks’ gestational age
requiring PPV with supplemental oxygen during resuscitation were enrolled. PPV was initiated with either oxygen (FiO2–0.30)+ iNO
at 20 ppm (iNO group) or oxygen (FiO2–0.30)+ nitrogen (placebo group). Oxygen was titrated targeting defined SpO2 per current
guidelines. After 10min, iNO/nitrogen was weaned stepwise per protocol and terminated at 17min.
RESULTS: Twenty-eight infants were studied (14 per group). The mean gestational age in both groups was similar. Cumulative FiO2
and rate of exposure to high FiO2 (>0.60) were significantly lower in the iNO group. There were no differences in HR, SpO2, and
need for intubation.
CONCLUSIONS: Administration of iNO as an adjunct during neonatal resuscitation is feasible without side effects. It diminishes
exposure to high levels of supplemental oxygen.
Pediatric Research (2020) 87:523–528; https://doi.org/10.1038/s41390-019-0643-x
INTRODUCTION
Survival of extremely premature babies has improved in the past two
decades.1–3 However, morbidities associated with prematurity, such
as necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH),
patent ductus arteriosus (PDA), neurodevelopmental delay, bronch-
opulmonary dysplasia (BPD), and retinopathy of prematurity (ROP)
present a significant burden for surviving premature infants.1–3 Of
these comorbidities, the latter two are associated with oxygen use
and mechanical ventilation.4–7 At present, optimal inspired oxygen
concentration for premature infants during resuscitation is still
uncertain. Current resuscitation guidelines recommend maintaining
set oxygen targets by minimizing oxygen exposure after birth.8,9
Administration of high levels of oxygen during resuscitation to
maintain target oxygen saturation may be harmful, due to the
generation of reactive oxygen species.10
Transition from fetal to neonatal circulation involves a complex
sequence of events during which pulmonary vascular resistance
drops dramatically in association with an increase in peripheral
vascular resistance.11–14 This cardiovascular adaptation at birth is
facilitated by the release of cortisol, catecholamines, and
vasodilator mediators, such as nitric oxide (NO) and prostaglandin
(PG) I2.
15–19 NO is particularly important as it regulates pulmonary
vascular tone at birth.20,21
NO is released from the vascular endothelium and plays a
critical role in vascular adaptation during the perinatal period.22,23
It is a powerful vasodilator, regulates pulmonary vascular tone,
facilitates fluid clearance from the alveoli, and secures the integrity
of the endothelial barrier.22,23 It activates vascular smooth muscle
cell soluble guanylate cyclase and cyclic guanosine monopho-
sphate production, leading to pulmonary smooth muscle relaxa-
tion, through the regulation of intracellular calcium levels.23,24 The
major emphasis of current resuscitation guidelines is on ventila-
tion, with the expectation that pulmonary vasodilation will
follow.8,9 Indeed, ventilation of the lungs with air alone promotes
reduction in pulmonary vascular resistance by release of
vasoactive mediators.14 However, these guidelines do not provide
any additional steps to facilitate pulmonary vasodilation other
than oxygen administration and lung expansion.
Both animal and human studies have shown that inhaled NO
(iNO) decreases pulmonary vascular resistance during
hypoxemia.25,26 Therefore, in premature infants needing resuscita-
tion, adding iNO during resuscitation may decrease pulmonary
vascular resistance, improve ventilation perfusion mismatch, and
reduce the need for excess oxygen. In hypoxic near-term lamb
model, exposure to 20 ppm of iNO at birth decreased pulmonary
vascular resistance and resulted in an increase in pulmonary blood
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flow.22 iNO administration during resuscitation has never been
attempted in human newborns.
The objective of this study was to test the hypothesis that iNO,
added as an adjunct to positive pressure ventilation (PPV), may
reduce the need for supplemental oxygen and may accelerate the
transition to neonatal circulation during resuscitation in premature
infants.
Our primary aims were: (1) to determine whether adding iNO
decreases supplemental oxygen exposure in preterm infants
requiring PPV during resuscitation as per NRP guidelines and (2) to
compare heart rate (HR), oxygen saturation, and need for
intubation between the two groups during the first 20 min of life.
Our secondary aims were: (1) to evaluate the effect of iNO
during resuscitation on immediate postnatal respiratory support in
the first 24 h and (2) to evaluate the effect of iNO on the incidence
of IVH, NEC, late-onset sepsis, PDA requiring treatment, ROP, BPD,
mortality, and Neonatal Intensive Care Unit length of stay.
METHODS
Study design and patients
This double-blind, randomized, placebo-controlled, pilot trial was
approved by the University of Oklahoma Health Sciences Center
Institutional Review Board. Written informed consent was
obtained prior to delivery. The study was registered with NIH
Clinical Trials (Clinicaltrials.gov, identifier NCT01220687). New
investigational drug approval was obtained from the Food and
Drug Administration (IND110317).
The target sample size for this pilot study was 40 (20 newborns in
each arm). The arbitrary sample size of 20 per group was chosen as
it was deemed large enough to adequately cover the whole
spectrum of the studied gestational age. Inclusion criteria were
newborn 25 0/7–31 6/7 weeks’ gestational age requiring continuous
positive airway pressure or PPV during delivery room (DR)
resuscitation/stabilization. Exclusion criteria were known complex
congenital anomalies of the heart or lungs and hydrops fetalis.
Randomization and masking
Infants meeting these criteria were randomly assigned to receive
either oxygen plus iNO diluted in N2 carrier gas (iNO group) or
oxygen in N2 carrier gas alone (placebo group). Subjects were
randomized using blocks of size two or four, chosen randomly, to
ensure proper balance of patients in each treatment arm throughout
the study. To ensure proper blinding, and because of the newborn’s
need for resuscitation, and thus study inclusion was unknown a priori,
equipment set-up based on the randomization group was performed
in advance. This was done so that DR personal would be unaware of
the treatment infants received, if resuscitation was administered.
Procedures
All neonatal resuscitations were done following NRP guidelines
(sixth edition).27 Immediately after birth, monitoring sensors were
placed for pre- (right arm) and post- (feet) ductal saturations using
two pulse oximeters (Masimo SET Radical-7 RDS-3™, Irvine, CA, USA).
Between 30 and 90 s, if the infant required PPV, those assigned to
the iNO group received 30% oxygen and the study gas. A dose of
20 ppm iNO is the standard approved dose for neonates with
persistent pulmonary hypertension of newborn (PPHN) and has
been shown to be safe in preterm infants during early postnatal
periods.28 Those in the placebo group received 30% oxygen and
nitrogen added to the oxygen source via a delivery port built into
the circuit. At 10min of respiratory support, the study gas (iNO or
placebo) was down-titrated by 5 ppm per minute until the
concentration reached 5 ppm, then reduced every minute by
1 ppm until study gas was terminated (a total of 17min). Data
collection continued for another 3min and ended at 20min (Fig. 1).
A T-piece resuscitator (NeoPuff™, Fisher & Paykel Healthcare,
Auckland, New Zealand) was used for PPV during initial respiratory
support. Oxygen administration was titrated to keep pre-ductal
saturations within the target range (1 min 60–65%, 2 min 65–70%,
3 min 70–75%, 4 min 75–80%, 5 min 80–85%, and 10min 85–95%).
Positive-end expiratory pressure was kept constant at 5 cm of
water. Peak inspiratory pressure was adjusted to ensure optimal
chest rise. No surfactant was administered during the first 20 min
after initiation of PPV.
The data capture device for this study was built around the iNO
vent, as follows:
The respiratory support section consisted of a blender, T-piece
resuscitator, and warmer/humidifier with an injector module to
deliver study gas (iNO) or nitrogen (placebo) with positive
pressure treatment.
The patient monitoring system consisted of pre- and post-
ductal saturations, HR, in-line FiO2, and pressure monitor for the T-
piece resuscitator.
The INO delivery/monitor consisted of an INOVENT Delivery
System™ (Model number 1605-9000-000, Datex Ohmeda, Mal-
linckrodt, USA), which includes an in-line oxygen analyzer, NO,
NO2, and delivered oxygen analyzer.
The whole set-up occupied the space of a standard transport
incubator.
Data capture and collection
Data were continuously collected during the study via an integrated
data acquisition system and software (BioPac™ MP 150 Data
Acquisition System, BIOPAC Systems, Inc. USA). Real-time display
consisted of a study clock, pre-ductal saturation, HR, analyzed and
delivered FiO2, and PPV pressure waveform. The resuscitation team
was blinded to both iNO delivery and display on the front of the INO
vent. Prior to the study, bench testing of this device was performed
in a SimnewB® non-breathing model to ensure accurate delivery of
oxygen and iNO to the nasal and hypo-pharyngeal area with the T-
Piece resuscitator. This test verified that there was no difference
between the analyzed and the delivered oxygen.
Statistical analysis
Descriptive statistics were computed for all demographic and clinical
variables. For bivariate group comparisons of continuous variables,
data were first assessed for normality using Shapiro–Wilk test and
then compared using Student’s t test or Wilcoxon–Mann–Whitney
test, as appropriate. Similarly, bivariate group comparisons of
categorical variables used the chi-square or Fisher’s exact test as
appropriate. The biometric data captured were then sampled at one
observation every 5 s, for a total of 240 observations per patient, for
clarity and analysis. Max FiO2, cumulative FiO2 exposure, FiO2 at
study end, HR, and pre- and post-ductal saturation percentages
were calculated from these measures for both groups, assessed for
normality, and compared using Student’s t test or
Wilcoxon–Mann–Whitney test, as appropriate. The rate of hyperoxia
(FiO2 > 0.60) over the study period was compared between the two
groups using Poisson test. In addition, functional principal
component (PC) analysis was used to estimate mean functional
curves of the biometrics over the study period and to identify
contiguous time points of significant variability between groups for
each outcome. PC scores were assigned to each subject within
regions of high variation and the scores between groups were
compared using Anderson–Darling test.29,30
RESULTS
This study was conducted between March, 2012 and February,
2017. Of the 171 mothers eligible for study participation, 95
provided written informed consent and were included. Of these
95 candidates, 61 were excluded. Thirty-four infants were
randomized at birth. Enrollment process was discontinued prior
to reaching our target (n= 40) due to slow recruitment. In all, 28
infants (14 in each group) were included in final analysis (Fig. 2).
Inhaled nitric oxide as an adjunct to neonatal resuscitation in premature. . .
K Sekar et al.
524
Pediatric Research (2020) 87:523 – 528
No significant inter-group differences were found in patient
demographics (Table 1).
Oxygen during resuscitation
Infants in the placebo group responded to PPV with oxygen
(+nitrogen) but required higher oxygen throughout resuscitation
compared to the iNO group. Infants randomly assigned to the iNO
(+oxygen) group received significantly less cumulative FiO2 when
summed across all sample points in the study period (p= 0.0012).
In addition, the maximum inspired oxygen required during the
study in the iNO group tended to be lower as compared to
the placebo group (0.39 vs. 0.48; p= 0.0536). This trend became
more pronounced at the end of 20 min between the iNO and the
placebo group, the iNO group still receiving lower oxygen
concentration compared to the placebo group (26% vs. 36%;
p= 0.0326; Fig. 3). The placebo group had 9 hyperoxia (FiO2 >
0.60) subjects combining for 708 FiO2 measures >0.60 over the
study period compared to 6 subjects in the iNO group combining
for 370 FiO2 measures >0.60 over the study period. The rate ratio
of hyperoxia for the placebo group compared to the iNO group
was 1.91 (95% confidence interval= 1.68, 2.18; p < 0.0001)
indicating that the rate of oxygen exposure >0.60 was significantly
higher in the placebo group than in the iNO group (Fig. 3).
HR during resuscitation
Throughout the resuscitations, the average HR appeared to be
lower in the iNO group than in the placebo group (Fig. 4). Mean
HR for iNO vs. placebo was 130 ± 46 vs. 139 ± 53 beats per minute
(bpm) at 5 min (p= 0.920) and 149 ± 46 vs. 161 ± 53 bpm at
10min (p= 0.354). At the end of 20 min, mean HR was 153 ± 46 vs.
168 ± 53 bpm. However, these differences were not statistically
significant (p= 0.111) (Fig. 4).
Pre- and post-ductal saturation
Mean pre- and post-ductal saturations (%) were not significantly
different between the groups at the end of the study (Pre: placebo
90.5 ± 5.7, iNO 82.8 ± 13.8; p= 0.757 and Post: placebo 79.9 ± 25.8,
iNO 78.2 ± 20.0; p= 0.849) (Fig. 3).
Need for intubation
Twenty-nine percent of babies in each group were intubated
during resuscitation (iNO 4/14, Placebo 4/14; p= 1.0).
Secondary outcomes
There were no significant group differences in any secondary
outcomes (Table 2). There were no between-group differences in
the need for supplemental oxygen or ventilator support in the
24 h following birth (data not shown).
There were no adverse events noted during resuscitation.
DISCUSSION
This preliminary study demonstrated that administration of iNO as
an adjunct during neonatal resuscitation is feasible without side
effects. Providing iNO in addition to oxygen during PPV for
extremely premature infants at birth is associated with a
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decreased need for supplemental oxygen treatments. Although
the iNO group appeared to have a lower average HR, it was not
statistically different.
This study was designed to determine whether the addition of
iNO would reduce the oxygen needed when premature neonates
require PPV, with or without intubation. Elevated pulmonary artery
pressure in the fetus, or “physiologic pulmonary hypertension,”
may persist in the immediate postnatal period and may not
respond to ventilation alone, as NRP guidelines recommend. In
these situations, iNO may augment pulmonary vasodilation, which
is essential in the prenatal-to-perinatal pulmonary transition, just
as it does in infants with PPHN.31
Studies of iNO in preterm infants with hypoxemia have shown
mixed results. In animal studies, iNO showed anti-inflammatory
properties, stimulated angiogenesis, increased alveolar growth,
improved surfactant function, and inhibited proliferation of
smooth muscle cells.32 In large randomized trials in premature
infants, none of the benefits seen in animal models were seen
when iNO was administered to reduce inflammation and chronic
lung disease,33 although a subset of preterm infants appeared to
benefit from it.28,34 Nevertheless, these trials have demonstrated
that iNO is safe and does not increase oxidative stress or lung
inflammation. iNO has never been evaluated in newborn
resuscitation for its vasodilator properties, which is essential for
extra-uterine adaptation.
In neonatal lambs resuscitated with 21%, 50%, or 100% oxygen
ventilation, those with 50% and 100% oxygen experienced a
greater initial decrease in pulmonary vascular resistance com-
pared with those resuscitated with 21% with blunted subsequent
response to iNO subsequently in the 100% oxygen group.
Asphyxiated lambs resuscitated with 100% oxygen showed
increased superoxide anions in pulmonary arteries compared to
21% oxygen resuscitation.26,35 These observations suggest that
resuscitation with high oxygen concentrations should be avoided
in premature infants as it may produce morbidities, such as ROP
and BPD.1–3 This has been shown in premature infants where
resuscitation with 30% compared to 90% oxygen causes less
oxidative stress and bronchopulmonary dysplasia.10 Therefore,
less oxygen exposure in premature infants during resuscitation is
preferable, and iNO during resuscitation may produce these
desired benefits. As observed in this study, iNO group required
less supplemental oxygen over the entire study period. In
addition, there was less exposure to hyperoxia (FiO2 > 0.60). This
is probably due to the vasodilator properties of iNO, improving
ventilation–perfusion mismatch, and reducing the need for
supplemental oxygen to maintain saturation targets. It is
interesting to note that the iNO group maintained a lower oxygen
requirement starting at 5–6min of resuscitation, even as the iNO
was slowly down-titrated, at 10 min of resuscitation. This finding
Table 1. Demographics
Parameter iNO group,
n= 14
Placebo group,
n= 14
p
BW (g) 1047 ± 322 1018 ± 322 0.91
GA (weeks)a 28.6 (27, 29.9) 28.1 (26.7, 29.1) 0.29
Apgar at 1 mina 4 (2, 5) 5 (4, 7) 0.19
Apgar at 5 mina 7 (6, 8) 8 (7, 8) 0.50
Race 0.78
Caucasian 10 10
Black 1 1
Native American 2 1
Hispanic 0 2
Others 1 0
Males 11 7 0.24
Antenatal steroid (any) 10/14 (71%) 11/14 (79%) 0.66
Antenatal steroid (complete
course)
9/14 (64%) 8/14 (57%) 0.70
Chorioamnionitis 3/14 (21%) 2/14 (14%) 0.62
ROM (>18 h) 4/14 (29%) 2/14 (14%) 0.36
Preeclampsia 5/14 (36%) 4/14 (29%) 0.69
ROM rupture of membrane
aMedian (interquartile range)
Eligible
(N = 171) Precipitous delivery (n = 3)
Non-qualifying exclusion–(n = 12)
Aged out, mother discharged (n = 31)
Precipitous delivery, crash CS (n = 18)
Equipment malfunction, no team
available, other = (n = 12)
Positive pressure not required
within 5 min of birth
(N = 3)
Placebo (N = 16)iNO (N = 15)
Consented mothers
(N = 95)
Randomized at birth
(N = 34)
Analyzed (n = 14)
excluded from analysis (n = 2)
no data capture
Analyzed (n = 14)
excluded from analysis (n = 1)
pulmonary hypoplasia
Other (n = 2)
Declined to participate (n = 59)
Excluded (N = 76)
Excluded (N = 61)
Fig. 2 Study enrollment and randomization
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indirectly indicates that the immediate vasodilator effect of iNO
appears to be sustained, despite having a very short half-life
(3–5 s). In contrast, the placebo group, after an initial positive
response to ventilation, began requiring greater supplemental
oxygen after 10 min.
The trend toward a lower HR in the iNO group was an
interesting observation. Although not statistically significant, at 5,
10, and 20min the average HR was 9, 12, and 15 bpm lower
respectively in this group. HR is the main determinant of cardiac
output in newborns. Cardiac output is dependent on the HR,
contractility, preload, and afterload.36 We speculate that the
observed differences may be due to improved lung perfusion
associated with improved oxygenation and better venous return
to the left side of the heart and increased left ventricular output.
Therefore, improved pulmonary blood flow (i.e., enhanced
preload) may be responsible for maintaining cardiac output and
keeping pre-ductal saturation within the targeted range in the iNO
group despite a lower HR. In addition, the mean HR in this study
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Table 2. Secondary outcomes
Variable iNO group Placebo group p Value
IVH ≥Gr 2 0/14 (0%) 2/14 (14%) 0.48
ROP > stage 2 1/11 (9%) 4/12 (33%) 0.33
PDA requiring treatment 1/14 (7%) 4/14 (29%) 0.14
Mechanical ventilation
(days)a
8.5 (1.5, 26) 14 (2, 29) 0.55
NIV (days)a 20.5 (6.5, 31) 15 (3, 23) 0.38
BPD (oxygen at 36 weeks) 5/12 (42%) 5/13 (38%) 0.87
Late-onset sepsis 0/12 (0%) 2/13 (15%) 0.48
Length of stay (days)a 70.5 (49, 108.5) 52 (48, 88) 0.35
Mortality 2/14 (14%) 1/14 (7%) 1.0
aMedian (interquartile range)
NIV non-invasive ventilation (HFNC > 2 lpm, CPAP, NIPPV)
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was similar to resuscitation studies using 90% and 100% oxygen in
premature babies.37
The secondary outcomes were not different between the
groups. In particular, the absence of IVH > 2 in either group is
consistent with previous observations in large clinical trials in
premature infants.28,33
One of the limitations of our study is the small sample size, but
this was known prior to study initiation and is consistent with its
design as a pilot project. We stopped recruitment before reaching
our initial target sample size. The study design required consent
prior to delivery, which required screening, and consenting from a
large number of parents. In addition, several consented mothers
were not enrolled due to precipitous delivery of extremely
premature babies, unavailability of the team, or the baby aged
out for enrollment. Nevertheless, we believe our final sample size
was adequate as a pilot trial.
CONCLUSIONS
Administration of iNO as an adjunct gas during neonatal
resuscitation is feasible and decreases the amount of exposure
to supplemental oxygen in very preterm infants. This was not
associated with any adverse events. These findings suggest that
iNO facilitates cardiopulmonary transition at birth. This novel
approach should be validated by large randomized trials.
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